Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Inhaler Stories

2012-09-13 02:27:56

REDWOOD CITY, Calif., Sept. 13, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of a randomized, double-blind Phase 2b dose-ranging study in which six doses of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP) ranging from 18 micrograms to 600 nanograms BID were delivered via metered-dose inhaler (GP MDI; PT001) to patients with moderate-to-severe COPD. In this study (NCT01566773) and the previously conducted dose-ranging GP MDI studies, a total of...

2012-09-12 11:35:55

Asthma study may prompt review of treatment guidelines, could reduce medication costs New research has shown that the millions of people who use corticosteroids prescribed daily to control mild asthma do no better than those who use them only when symptoms occur. These findings suggest a potential new treatment option that could change international standards of care, reduce patients' pharmacy costs, limit long-term exposure to corticosteroids and enable flexibility in managing the...

2012-09-02 18:22:46

VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study - a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) - at the annual meeting of the European Respiratory Society in Vienna, Austria. As previously announced, EP-101 demonstrated a rapid onset, dose-related, statistically significant improvement in lung function compared to placebo....

2012-08-30 23:00:45

ASA Offers Easy-to-Use Device for Persons with Complicated Med Routines Pittsburgh, PA (PRWEB) August 29, 2012 Managing a complicated medication schedule can be a challenge for anyone without a medical background, but The Dispense-A-Pill l system offered by Automated Security Alert is an option to make a daunting task a very simple one. The Pittsburgh-based health care company is announcing an advanced option that not only delivers pills on a pre-programmed schedule, but medications that...

2012-08-21 02:26:56

ORLANDO, Fla., Aug. 21, 2012 /PRNewswire/ -- Nephron Pharmaceuticals Corporation (Nephron) is proud to announce Asthmanefrin, a fast acting, safe and effective over-the-counter (OTC) alternative to the discontinued Primatene® Mist chlorofluorocarbon (CFC) inhaler. Asthmanefrin will provide relief for millions of former Primatene® Mist users. The Primatene® Mist CFC inhaler was removed from the market by the Food and Drug Administration (FDA) and the Environmental Protection...

2012-08-06 14:21:08

MADISON, Wis., Aug. 6, 2012 /PRNewswire/ -- Asthmapolis announced today that it will be expanding its asthma study at Woodland Healthcare in Woodland, Calif. to also include patients from Mercy Medical Group, another Dignity Health system, located in neighboring Sacramento, Calif. "We're excited to expand the study to include the patients and physicians at Mercy Medical Group," noted David Van Sickle, co-founder and CEO of Asthmapolis. "With the addition of this system, thousands of...

2012-07-18 02:26:18

Primatene® Mist Critical For Millions of Asthmatics Lacking Health Insurance; All Manufacturer's Net Profits from Sales of Primatene® Mist will be Donated to Charity WASHINGTON, July 18, 2012 /PRNewswire-USNewswire/ -- The makers of Primatene® Mist have launched a campaign to put the over-the-counter inhaler back on the market in the United States, after it was banned because it contains a small amount of chlorofluorocarbons (CFCs), leaving millions of asthmatics...

2012-07-17 10:24:52

SEATTLE, July 17, 2012 /PRNewswire/ -- Asthmapolis, a Wisconsin-based company dedicated to advancements in asthma treatment, partnered with Synapse to develop breakthrough technologies for asthma treatment. Combining medication sensors, mobile applications, and analytics, the Asthmapolis sensor attaches to existing rescue inhalers to collect data such as when and where patients experience asthma conditions. Having recently received U.S. Food and Drug Administration clearance, Asthmapolis will...

2012-07-10 22:21:02

MADISON, Wis., July 11, 2012 /PRNewswire-iReach/ -- Asthmapolis announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its asthma sensor system and associated software to healthcare providers and their patients. (Photo: http://photos.prnewswire.com/prnh/20120711/CG38057) "We are thrilled to have achieved this important milestone to support our mission of providing tools to help patients and their healthcare providers better understand and...

2012-07-04 22:20:47

OXFORD, England, July 5, 2012 /PRNewswire/ -- Prosonix (Oxford, UK) announced that it has signed a Collaborative Research Agreement with Imperial College London to accelerate the development of engineered Multi-component Particles (MCPs(TM)) as respiratory medicines. The collaboration will see Prosonix working closely with Dr Omar Usmani, an internationally recognised expert in respiratory diseases and inhaled drug delivery at the College's National Heart and Lung...